Enliven Therapeutics (ELVN) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ELVN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Enliven Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$45.89 |
| 52 Week High | US$48.53 |
| 52 Week Low | US$14.79 |
| Beta | 0.49 |
| 1 Month Change | 58.08% |
| 3 Month Change | 68.68% |
| 1 Year Change | 155.37% |
| 3 Year Change | 132.83% |
| 5 Year Change | n/a |
| Change since IPO | 93.22% |
Recent News & Updates
Recent updates
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious
Jan 13Companies Like Enliven Therapeutics (NASDAQ:ELVN) Are In A Position To Invest In Growth
Aug 15
Enliven Therapeutics: Awaiting Additional Trial Data
Apr 22We Think Enliven Therapeutics (NASDAQ:ELVN) Can Afford To Drive Business Growth
Apr 01Enliven's Early Data Stands Out From Peers
Jan 07Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Dec 14We Think Enliven Therapeutics (NASDAQ:ELVN) Can Afford To Drive Business Growth
Aug 29Shareholder Returns
| ELVN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.3% | -3.0% | 1.3% |
| 1Y | 155.4% | 26.4% | 34.7% |
Return vs Industry: ELVN exceeded the US Pharmaceuticals industry which returned 30.7% over the past year.
Return vs Market: ELVN exceeded the US Market which returned 39.4% over the past year.
Price Volatility
| ELVN volatility | |
|---|---|
| ELVN Average Weekly Movement | 9.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ELVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ELVN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 60 | Rick Fair | www.enliventherapeutics.com |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc. Fundamentals Summary
| ELVN fundamental statistics | |
|---|---|
| Market cap | US$2.78b |
| Earnings (TTM) | -US$103.69m |
| Revenue (TTM) | n/a |
Is ELVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELVN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$103.69m |
| Earnings | -US$103.69m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ELVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/21 15:03 |
| End of Day Share Price | 2026/04/21 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enliven Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Salveen Richter | Goldman Sachs |
| Robert Burns | H.C. Wainwright & Co. |